Mutagenesis, Vol. 14, No. 1, 5-22,
January 1999
© 1999 UK Environmental Mutagen Society/Oxford University Press
Evaluation of the mouse lymphoma tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test
1 Division of Genetics and Mutagenesis, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158, 2 Daiichi Pharmaceutical Co. Ltd, 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134, 3 Food and Drug Safety Center, 729-5 Ochiai, Hadano-shi, Kanagawa 257, 4 Otsuka Pharmaceutical Co. Ltd, 463-10 Kagasuno, Kawachi-cho, Tokushima-shi, Tokushima 771-01, 5 Takeda Chemical Industry Ltd, Himuro-co, Takatsuki-shi, Osaka 569, 6 Japan Tobacco Inc., 6-2 Umegaoka, Midori-ku, Yokohama-shi, Kanagawa 227, 7 Division of Risk Assessment, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158, Japan
In order to evaluate the utility of the mouse lymphoma assay (MLA) for detecting in vitro clastogens and spindle poisons and to compare it with the in vitro chromosomal aberration test (CA), we conducted an international collaborative study of the MLA that included 45 Japanese laboratories and seven overseas laboratories under the cooperation of the Ministry of Health and Welfare of Japan and the Japanese Pharmaceutical Manufacturer's Association. We examined 40 chemicals; 33 were reportedly positive in the CA but negative in the bacterial reverse mutation assay, six were negative in both assays and one was positive in both. We assayed mutations of the thymidine kinase (TK) locus (tk) of L5178Y tk+/– mouse lymphoma cells using the microwell method. According to our standard protocol, cells were exposed to the chemical for 3 h, cultured for 2 days and TK-deficient mutants were expressed in 96-well plates under trifluorothymidine. Each chemical was coded and tested by two or three laboratories. Among the 34 CA-positive chemicals, positive MLA results were obtained for 20 and negative results were obtained for nine. The remaining five chemicals were inconclusive or equivocal because of discrepant inter-laboratory results or reproduced discrepant results, respectively. Among the six CA-negative chemicals, one was negative in the MLA, two were positive and three were inconclusive. Thus, the MLA could detect only 59% (20/34) of CA-positive chemicals. We concluded that the MLA was not as sensitive as the CA. Some MLA-negative chemicals evoked positive responses in the CA only after long continuous treatment. These might also be genotoxic in the MLA with long continuous treatment. Improvement of the MLA protocol, including alteration of the duration of the treatment, might render the MLA as sensitive as the CA.
8 To whom correspondence should be addressed. Tel: +81 3 3700 9847; Fax: +81 3 3700 2348; Email: sofuni{at}nihs.go.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Wang, J. R. Sawyer, L. Chen, T. Chen, M. Honma, N. Mei, and M. M. Moore The Mouse Lymphoma Assay Detects Recombination, Deletion, and Aneuploidy Toxicol. Sci., May 1, 2009; 109(1): 96 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Oakes, H. Ritchie, P. Woodman, E Narup, M Moscova, K Picker, and W. Webster Genotoxicity studies of a desealant solvent mixture, SR-51(R) Toxicology and Industrial Health, February 1, 2009; 25(1): 5 - 13. [Abstract] [PDF]
|
|
|
|
 |
|
 P.A. Cahill, A.W. Knight, N. Billinton, M.G. Barker, L. Walsh, P.O. Keenan, C.V. Williams, D.J. Tweats, and R.M. Walmsley The GreenScreen(R) genotoxicity assay: a screening validation programme Mutagenesis, March 1, 2004; 19(2): 105 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Speit and O. Merk Evaluation of mutagenic effects of formaldehyde in vitro: detection of crosslinks and mutations in mouse lymphoma cells Mutagenesis, May 1, 2002; 17(3): 183 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Parry Applications and interpretation of data obtained in the mouse lymphoma tk assay Mutagenesis, May 1, 1999; 14(3): 255 - 255. [Full Text] [PDF]
|
|
|
|
|
|
J. Cole, K. Harrington-Brock, and M. M. Moore The mouse lymphoma assay in the wake of ICH4—where are we now? Mutagenesis, May 1, 1999; 14(3): 265 - 270. [Full Text] [PDF]
|
|
|
|
|
|
M. M. Moore, K. Harrington-Brock, and J. Cole Issues for conducting the microtiter version of the mouse lymphoma thymidine kinase (tk) assay and a critical review of data generated in a collaborative trial using the microtiter method Mutagenesis, May 1, 1999; 14(3): 271 - 281. [Full Text] [PDF]
|
|
|
|
|
|
M. Honma, L.-S. Zhang, H. Sakamoto, M. Ozaki, K. Takeshita, M. Momose, M. Hayashi, and T. Sofuni The need for long-term treatment in the mouse lymphoma assay Mutagenesis, January 1, 1999; 14(1): 23 - 29. [Abstract] [Full Text] [PDF]
|
|